Israeli/American biotech company Andain Inc. says that it has developed an “innovative lipid-based drug delivery nano-particles capable of carrying hydrophilic and hydrophobic drugs to a targeted human organ with timely drug release capabilities” and announced that it has developed an inhalation solution for the treatment of COPD using the technology.
The company did not provide any other details about the inhalation solution but said that it “intends to approach the initial market segment of respiratory intensive care units to treat VAP (ventilator-associated pneumonia)” and said of the delivery technology: “After the nano-particles release the drug directly to the targeted organ, they brake-down [sic] to their natural ingredients and are absorbed into the natural metabolism with no adverse affects.”
Andain President and CEO Sam Elimelech said, “Our initial human respiratory tests show superb lung dispersion and distribution, preventing any residual damage providing safe and extremely efficient respiratory drug delivery method capable to carry any combinations of drugs. We have a developed efficient delivery system capable to deliver almost any drug usually systemically administered to be targeted to a specific organ and enabling to dramatically reduce the needed treatment dosage.”
Read the Andain press release.
